Crinetics Pharmaceuticals Inc (CRNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) has a cash flow conversion efficiency ratio of -0.079x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-94.19 Million) by net assets ($1.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Crinetics Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Crinetics Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Crinetics Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crinetics Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See how well can Crinetics Pharmaceuticals Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vietnam JSCmmercial Bank for Industry and Trade
VN:CTG
|
-0.013x |
|
Sirius XM Holding Inc
NASDAQ:SIRI
|
0.023x |
|
Toro Co
NYSE:TTC
|
0.018x |
|
Ingenic Semiconductor
SHE:300223
|
0.006x |
|
Baloise Holding AG
SW:BALN
|
0.211x |
|
Vanguard International Semiconductor
TWO:5347
|
0.092x |
|
SARTORIUS (UNSP.ADS)/1/5
F:SRT0
|
0.049x |
|
Rexford Industrial Realty Inc
NYSE:REXR
|
0.017x |
Annual Cash Flow Conversion Efficiency for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Crinetics Pharmaceuticals Inc from 2016 to 2025. View today's stock price for Crinetics Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $992.08 Million | $-377.92 Million | -0.381x | -123.33% |
| 2024-12-31 | $1.32 Billion | $-225.97 Million | -0.171x | +44.71% |
| 2023-12-31 | $539.11 Million | $-166.31 Million | -0.308x | +15.30% |
| 2022-12-31 | $316.33 Million | $-115.20 Million | -0.364x | -36.47% |
| 2021-12-31 | $331.94 Million | $-88.59 Million | -0.267x | +27.32% |
| 2020-12-31 | $168.92 Million | $-62.03 Million | -0.367x | +7.26% |
| 2019-12-31 | $117.14 Million | $-46.38 Million | -0.396x | -226.02% |
| 2018-12-31 | $160.22 Million | $-19.46 Million | -0.121x | -119.25% |
| 2017-12-31 | $-15.02 Million | $-9.48 Million | 0.631x | -28.41% |
| 2016-12-31 | $-6.20 Million | $-5.47 Million | 0.881x | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more